Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab
Letter to the Editor
- 559 Downloads
KeywordsVascular Endothelial Growth Factor Bevacizumab Oxaliplatin Pemetrexed Arteriovenous Malformation
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
- 2.Kindler HL, Karrison T, Lu C, Gandara DR, Stevenson J, Krug L, Janne P, Guterz TL, Stadler WM, Vokes EE (2005) A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM). Proc Am soc Clin Oncol 24:7019 (abstract)Google Scholar
- 3.Sadick H, Riedel F, Naim R, Goessler U, Hormann K, Hafner M, Lux A (2005) Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 90:818–828PubMedGoogle Scholar
© Springer-Verlag 2006